Nykode Therapeutics proposes chair of Zealand Pharma to lead own board

The board at Norwegian biotech firm Nykode Therapeutics, which is led by Danish CEO Michael Engsig, has proposed that the current Chairman at Zealand Pharma Martin Nicklasson also chairs the board at Nykode.

Martin Nicklasson, chair of Zealand Pharma, has been proposed as chair of Nykode Therapeutics | Photo: Zealand Pharma / PR

When Norwegian biotech firm Nykode Therapeutics meets for its general assembly on Dec. 22, a new face will join as chairman of the board of directors.

The company, which was named Vaccibody until recently, announces the board's decision to propose Martin Nicklasson as the new chair, replacing Anders Tuv, who has left the role but has remained as an ordinary member of the board.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs